Recommendations for the management of autoinflammatory diseases
Por:
Ter Haar NM, Oswald M, Jeyaratnam J, Anton-Lopez J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M and Kuemmerle-Deschner JB
Publicada:
1 sep 2015
Ahead of Print:
24 jun 2015
Categoría:
Rheumatology
Resumen:
Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and (paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with >= 80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD.
Filiaciones:
Ter Haar NM:
Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands Department of Paediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Oswald M:
Division of Paediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
Jeyaratnam J:
Department of Paediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
Anton-Lopez J:
Paediatric Rheumatology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
Barron KS:
Division of Intramural Research, National Institute of Health, Bethesda, USA
Brogan PA:
Department of Rheumatology, UCL Institute of Child Health, London, UK
Cantarini L:
Rheumatology Unit, Policlinico le Scotte, University of Siena, Siena, Italy
Galeotti C:
Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, Paris, France
Grateau G:
Department of Internal Medicine, APHP, Hôpital Tenon, University Pierre-et-Marie-Curie, Paris, France
Hentgen V:
French Reference Centre for Auto-Inflammatory Diseases in Children, Centre Hospitalier de Versailles, Le Chesnay Cedex, France
Hofer M:
Department of Paediatrics, University of Lausanne, Lausanne, Switzerland
Kallinich T:
Department of Paediatric Pneumology and Immunology, Charité University Medicine, Berlin, Germany
Kone-Paut I:
Department of Paediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France
Lachmann HJ:
National Amyloidosis Centre, University College London Medical School, London, UK
Ozdogan H:
Division of Rheumatology, Cerrahpasa Ic Hastaliklari Klinigi, University Istanbul, Istanbul, Turkey
Ozen S:
Department of Paediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Russo R:
Service of Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina
Simon A:
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Uziel Y:
Department of Paediatrics, Meir Medical Center, Tel-Aviv University, Tel-Aviv, Israel
Wouters C:
Department of Microbiology and Immunology, University Hospital Leuven, Leuven, Belgium
Feldman BM:
Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada
Vastert SJ:
Department of Paediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Wulffraat NM:
Department of Paediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Benseler SM:
Department of Paediatrics, Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, Canada
Frenkel J:
Department of Paediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
Gattorno M:
Division of Paediatrics II, G. Gaslini Institute, Genoa, Italy
Kuemmerle-Deschner JB:
Division of Paediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
Green Submitted, Bronze
|